Literature DB >> 19841162

FROUNT is a common regulator of CCR2 and CCR5 signaling to control directional migration.

Etsuko Toda1, Yuya Terashima, Tsuyoshi Sato, Kenzo Hirose, Shiro Kanegasaki, Kouji Matsushima.   

Abstract

FROUNT is a known CCR2-binding protein that facilitates monocyte/macrophage infiltration. Here we report that FROUNT also binds to the C-terminal region of CCR5 and enhances CCR5-mediated cellular chemotaxis. We show that FROUNT overexpression enhances the directionality of chemotaxis, while FROUNT suppression results in impaired responsiveness. Furthermore, we found an increase in consolidated pseudopodium formation in FROUNT-overexpressing cells (FNT cells) on uniform stimulation with CCL4 (MIP1-beta), a specific ligand of CCR5. In most FNT cells, one to two pseudopodia directed toward higher chemokine concentration were found, whereas most FNT-suppressed cells had multiple pseudopodia. The data indicate that FROUNT is involved in sensing and amplifying a shallow extracellular chemokine gradient that leads to a limited number of accurate pseudopodia directed toward the chemokine concentration. In addition to its separate roles in CCR2- and CCR5-mediated chemotaxis, FROUNT, as a common regulator of these receptors, possibly plays a crucial role in the recruitment of immune cells expressing these receptors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19841162     DOI: 10.4049/jimmunol.0803469

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Identification and Preparation of a Novel Chemokine Receptor-Binding Domain in the Cytoplasmic Regulator FROUNT.

Authors:  Akihiro Sonoda; Sosuke Yoshinaga; Kaori Yunoki; Soichiro Ezaki; Kotaro Yano; Mitsuhiro Takeda; Etsuko Toda; Yuya Terashima; Kouji Matsushima; Hiroaki Terasawa
Journal:  Mol Biotechnol       Date:  2017-05       Impact factor: 2.695

Review 2.  The roles of the nuclear pore complex in cellular dysfunction, aging and disease.

Authors:  Stephen Sakuma; Maximiliano A D'Angelo
Journal:  Semin Cell Dev Biol       Date:  2017-05-12       Impact factor: 7.727

3.  Buprenorphine Increases HIV-1 Infection In Vitro but Does Not Reactivate HIV-1 from Latency.

Authors:  Germán Gustavo Gornalusse; Lucia N Vojtech; Claire N Levy; Sean M Hughes; Yeseul Kim; Rogelio Valdez; Urvashi Pandey; Christina Ochsenbauer; Rena Astronomo; Julie McElrath; Florian Hladik
Journal:  Viruses       Date:  2021-07-27       Impact factor: 5.818

4.  Phosphoproteomic characterization of the signaling network resulting from activation of the chemokine receptor CCR2.

Authors:  Cheng Huang; Simon R Foster; Anup D Shah; Oded Kleifeld; Meritxell Canals; Ralf B Schittenhelm; Martin J Stone
Journal:  J Biol Chem       Date:  2020-04-02       Impact factor: 5.157

5.  Targeting FROUNT with disulfiram suppresses macrophage accumulation and its tumor-promoting properties.

Authors:  Yuya Terashima; Etsuko Toda; Meiji Itakura; Mikiya Otsuji; Sosuke Yoshinaga; Kazuhiro Okumura; Francis H W Shand; Yoshihiro Komohara; Mitsuhiro Takeda; Kana Kokubo; Ming-Chen Chen; Sana Yokoi; Hirofumi Rokutan; Yutaka Kofuku; Koji Ohnishi; Miki Ohira; Toshihiko Iizasa; Hirofumi Nakano; Takayoshi Okabe; Hirotatsu Kojima; Akira Shimizu; Shiro Kanegasaki; Ming-Rong Zhang; Ichio Shimada; Hiroki Nagase; Hiroaki Terasawa; Kouji Matsushima
Journal:  Nat Commun       Date:  2020-01-30       Impact factor: 14.919

6.  Nucleoporin 85 interacts with influenza A virus PB1 and PB2 to promote its replication by facilitating nuclear import of ribonucleoprotein.

Authors:  Yue-Huan Ling; Hao Wang; Mei-Qing Han; Di Wang; Yi-Xiang Hu; Kun Zhou; Yan Li
Journal:  Front Microbiol       Date:  2022-08-16       Impact factor: 6.064

Review 7.  New insights in chemokine signaling.

Authors:  Daniel F Legler; Marcus Thelen
Journal:  F1000Res       Date:  2018-01-23

8.  Disulfiram Produces Potent Anxiolytic-Like Effects Without Benzodiazepine Anxiolytics-Related Adverse Effects in Mice.

Authors:  Akiyoshi Saitoh; Yoshifumi Nagayama; Daisuke Yamada; Kosho Makino; Toshinori Yoshioka; Nanami Yamanaka; Momoka Nakatani; Yoshino Takahashi; Mayuna Yamazaki; Chihiro Shigemoto; Misaki Ohashi; Kotaro Okano; Tomoki Omata; Etsuko Toda; Yoshitake Sano; Hideyo Takahashi; Kouji Matsushima; Yuya Terashima
Journal:  Front Pharmacol       Date:  2022-03-07       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.